diseases of upper digestive tract
Conditions
Interventions
group A:rabeprazole10mg qid+amoxicillin 750mg qid 14days
group B:rabeprazole 20mg qid+amoxicillin 750mg qid 14days
group C:rabeprazole 20mg bid+bismuth 220mg bid+ Amoxicillin 1g bid+clarithromycin 500mg bid 14days
Sponsors
Daping Hospital, the Third Military Medical University, Chongqing, China
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-70 years old, male or female; 2. 13C breath test positive or the result of rapid ureas test above ++; 3. Endoscopy diagnosed chronic gastritis, uncomplicated duodenal ulcer patients, relatives of patients with gastric or request a healer; 4. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Using antibiotics, bismuth, probiotics, H2 receptor antagonists, PPI and drugs metaboliced through the cytochrome P450 2C19 Within four weeks before treatment; 2. Pregnant or lactating women; 3. Patients are also taking non-steroidal anti-inflammatory drugs, adrenocorticotro or alcohol; 4. the presence of other study evaluated the impact of this serious disease such as severe liver disease, heart disease, kidney disease, cancer and other diseases; 5. used in this study for patients with drug allergy; 6. gastrectomy patients or gastric mucosa with high-grade intraepithelial neoplasia; 7. Participated in studies of other drugs before using this study medication within three months; 8. Other factors that were difficult to complete the follow-up or affecting compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Effects Rate;The patient's compliance; | — |
Countries
China
Contacts
Public ContactChunhui Lan
Outcome results
None listed